ReviewNature reviews. Neurology2020
Towards treating progressive multiple sclerosis.
Review in Nature reviews. Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in neurology · 2024Pooled it
- SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Therapeutic evaluation of immunomodulators and immunosuppressants in progressive multiple sclerosis: summary of a Cochrane systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Neurotrophic factors in multiple sclerosis.Frontiers in immunology · 2025Review
- Progressive multiple sclerosis: A bibliometric analysis.Medicine · 2024Article
- PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation.Nature communications · 2023Article
- Emerging roles of GPR109A in regulation of neuroinflammation in neurological diseases and pain.Neural regeneration research · 2023Review
- Review
- The Anti-Inflammatory PeptideCells · 2023Article
- The role of glial cells in multiple sclerosis disease progression.Nature reviews. Neurology · 2022Review
- Choroid plexus-selective inactivation of adenosine AJournal of neuroinflammation · 2022Article
- Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Review
- CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Positron emission tomography in multiple sclerosis - straight to the target.Nature reviews. Neurology · 2021Review
- Neurology at the crossroads.Nature reviews. Neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
33024328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.